Table 1.
Dissection (n = 37) | Preservation (n = 37) | P | |
---|---|---|---|
Clinical variables | |||
Age, years | 64.8 ± 8.9 | 65.3 ± 9.1 | 0.8028 |
Sex, male/female | 24 (64.9%) /13 (35.1%) | 23 (62.2%)/ 14 (37.8%) | 1.0000 |
Performance status, 0/1 | 36 (97.3%)/ 1 (2.7%) | 36 (97.3%)/ 1 (2.7%) | 1.0000 |
Body mass index, kg/m2 | 21.1 ± 2.8 | 21.4 ± 2.4 | 0.5954 |
NCCN resectability status | |||
R | 29 (78.4%) | 30 (81.1%) | 0.7105 |
BR‐PV | 7 (18.9%) | 5 (13.5%) | |
BR‐A | 1 (2.7%) | 2 (5.4%) | |
Tumor size, mm | 23.0 ± 7.2 | 23.8 ± 8.1 | 0.6513 |
Biliary drainage | 17 (46.0%) | 23 (62.2%) | 0.2433 |
Neoadjuvant therapy | 16 (43.2%) | 12 (32.4%) | 0.4725 |
Preoperative radiation therapy | 2 (5.4%) | 4 (10.8%) | 0.6741 |
CEA, ng/ml | 27.6 ± 126.0 | 5.2 ± 5.8 | 0.2865 |
CA19‐9, U/ml | 320.5 ± 827.5 | 765.2 ± 1713.9 | 0.1612 |
DUPAN‐2, U/ml | 305.0 ± 415.8 | 282.8 ± 600.3 | 0.8756 |
Operation time, min | 450.3 ± 111.7 | 491.4 ± 108.8 | 0.1134 |
Blood loss, ml | 892.4 ± 565.8 | 1024.7 ± 649.1 | 0.3530 |
Portal vein resection | 16 (43.2%) | 21 (56.8%) | 0.3525 |
Blood transfusion | 5 (13.5%) | 5 (13.5%) | 1.0000 |
Pathological invasion of SMA nerve plexus | 2 (5.4%) | 3 (8.1%) | 1.0000 |
Residual tumor, R0/R1 | 35 (94.6%)/ 2 (5.4%)` | 31 (83.8%)/ 6 (16.2%) | 0.2611 |
SMA margin | 0 (0.0%) | 1 (2.7%) | |
Dissected pancreatic margin | 2 (5.4%) | 5 (13.5%) | |
UICC stage (7th edition) | |||
IA | 3 (8.1%) | 3 (8.1%) | 0.9188 |
IB | 1 (2.7%) | 0 (0.0%) | |
IIA | 9 (24.3%) | 7 (18.9%) | |
IIB | 21 (56.8%) | 24 (64.9%) | |
III | 1 (2.7%) | 1 (2.7%) | |
IV | 2 (5.4%) | 2 (5.4%) |
Data are expressed as mean ± standard deviation or n (%).
Abbreviations: BR‐A, borderline resectable with arterial invasion; BR‐PV, borderline resectable with portal vein invasion; CA19‐9, cancer antigen 19‐9; CEA, carcinoembryonic antigen; R, resectable; SMA, superior mesenteric artery; UICC, Union for International Cancer Control.